Deletion 11q is an important prognostic factor1

Del 11q occurs in about 20% of patients with CLL1

  • It is associated with extensive lymphadenopathy, rapid disease progression, and poor survival1

Changes in iwCLL Guidelines2,3

  Baseline testing for 11q deletion
  iwCLL 2018 iwCLL 2008
General practice ALWAYS Desirable
Clinical trial ALWAYS Always

Bolding indicates updates.

CLL=chronic lymphocytic leukemia, Del=deletion, iwCLL=International Workshop on Chronic Lymphocytic Leukemia.

Other CLL biomarkers

What other genetic markers can provide prognostic value?

See how

References: 1. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. 2. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. 3. Hallek M, Cheson BD, Catovsky D, et al; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.

Share this page

You are now leaving www.cllbiomarkers.com

By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit.

For any questions about the Pharmacyclics Privacy Policy, please visit www.pharmacyclics.com and click on the Privacy Policy link.